Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions
This survey study (n=10) asked experienced psilocybin therapists and research staff to recommend music that best supports the lead-up to and peak of psilocybin sessions aiming to elicit mystical experiences. It finds that peak-period music is typically regular, predictable and gradually building with a continuous forward motion and relatively low perceptual brightness, offering practical guidance for selecting or composing music to optimise peak psychedelic experiences in research and therapy.
Authors
- Roland Griffiths
- Frederick Barrett
Published
Abstract
Psilocybin is a classic (serotonergic) hallucinogen (“psychedelic” drug) that may occasion mystical experiences (characterized by a profound feeling of oneness or unity) during acute effects. Such experiences may have therapeutic value. Research and clinical applications of psychedelics usually include music listening during acute drug effects, based on the expectation that music will provide psychological support during the acute effects of psychedelic drugs, and may even facilitate the occurrence of mystical experiences. However, the features of music chosen to support the different phases of drug effects are not well-specified. As a result, there is currently neither real guidance for the selection of music nor standardization of the music used to support clinical trials with psychedelic drugs across various research groups or therapists. A description of the features of music found to be supportive of mystical experience will allow for the standardization and optimization of the delivery of psychedelic drugs in both research trials and therapeutic contexts. To this end, we conducted an anonymous survey of individuals with extensive experience administering psilocybin or psilocybin-containing mushrooms under research or therapeutic conditions, in order to identify the features of commonly used musical selections that have been found by therapists and research staff to be supportive of mystical experiences within a psilocybin session. Ten respondents yielded 24 unique recommendations of musical stimuli supportive of peak effects with psilocybin, and 24 unique recommendations of musical stimuli supportive of the period leading up to a peak experience. Qualitative analysis (expert rating of musical and music-theoretic features of the recommended stimuli) and quantitative analysis (using signal processing and music-information retrieval methods) of 22 of these stimuli yielded a description of peak period music that was characterized by regular, predictable, formulaic phrase structure and orchestration, a feeling of continuous movement and forward motion that slowly builds over time, and lower perceptual brightness when compared to pre peak music. These results provide a description of music that may be optimally supportive of peak psychedelic experiences. This description can be used to guide the selection and composition of music for future psychedelic research and therapy sessions.
Research Summary of 'Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions'
Introduction
Psychedelic drugs such as psilocybin can occasion profound alterations in perception and consciousness, including mystical or non-dual experiences characterised by a sense of oneness, positive mood, and difficulty verbalising the experience. Earlier research and recent clinical trials have suggested therapeutic potential for psychedelics in mood disorders and addiction, and mystical-type experiences have been linked to therapeutic benefit. Music is commonly used during psychedelic sessions because it is believed to provide psychological support and to facilitate such peak experiences, but the specific musical features that are supportive across different phases of the drug effect have not been well quantified or standardised. Slevc and colleagues set out to identify and characterise the musical features that experienced psilocybin guides report as supportive of mystical peak experiences and of the period leading up to a peak (‘‘pre-peak’’). The investigators conducted an anonymous online survey of therapists and guides with extensive psilocybin-guiding experience, then applied both qualitative expert ratings and quantitative Music Information Retrieval (MIR) analyses to the recommended musical selections. The aim was to generate an empirically grounded description of music that may be optimal for supporting peak psychedelic experiences and to provide a foundation for future standardisation and experimental testing.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Frontiers in Psychology, 8. https://doi.org/10.3389/fpsyg.2017.01238
References (19)
Papers cited by this study that are also in Blossom
Barrett, F. S., Griffiths, R. R. · Current Topics in Behavioral Neurosciences (2017)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Show all 19 referencesShow fewer
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Nichols, D. E. · Pharmacological Reviews (2016)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Cited By (20)
Papers in Blossom that reference this study
Henningfield, J. E., Barrett, F. S., Evans, S. M. et al. · Journal of Psychopharmacology (2026)
Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)
Macconnel, H. A., Earleywine, M., Radowitz, S. · OSF Preprints (2024)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Oehen, P., Gasser, P. · Frontiers in Psychiatry (2022)
Gandy, S. · Journal of Psychedelic Studies (2022)
Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)
Golden, T. L., Magsamen, S., Sandu, C. C. et al. · Current Topics in Behavioral Neurosciences (2022)
Show all 20 papersShow fewer
Williams, M. L., Korevaar, D., Harvey, R. et al. · Frontiers in Psychiatry (2021)
Bathje, G. J., Fenton, J., Pillersdorf, D. et al. · Journal of Humanistic Psychology (2021)
O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)
Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Barrett, F. S., Preller, K. H., Herdener, M. et al. · Cerebral Cortex (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.